You have to think beyond a patient's disease process and think about how they engage with the healthcare system, explained Jason Mitchell, MD, chief medical and clinical transformation officer, Presbyterian Healthcare Services.
You have to think beyond a patient's disease process and think about how they engage with the healthcare system, explained Jason Mitchell, MD, chief medical and clinical transformation officer, Presbyterian Healthcare Services.
Transcript
In a fully transitioned value-based care landscape, what are things the healthcare system would be focused on or paying attention to that it isn’t right now?
When you think about really dropping the total cost of care and providing the best healthcare to the people you’re caring for, you’ve got to think of them when they’re not in your hospitals and not in your clinics. What’s going on in their home? What’s going on in their community? What’s your employment look like? Education? Those type of things. I think it really is getting back to those social determinants, getting back to the health of the community, and really thinking about those things as an organization and invest into those things as an organization. I think that’s a lot of the pieces that get left behind, historically.
I think you also have to think beyond someone’s disease process. You have to think about how people engage in healthcare and what their behaviors are so that you can do interventions to help with those types of behaviors and meet their needs. It’s no longer a once-size-fits-all but it’s really how do you give individualized care to an entire population?
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
Depth of Responses, PFS in Transplant-Ineligible Patients Match Overall Findings in CEPHEUS
June 2nd 2025Quadruplet therapy is now the accepted standard for patients newly diagnosed with myeloma who are ineligible for transplant; there is debate whether all newly diagnosed patients should have this regimen.
Read More
Multicancer Detection Assays Remain Largely Elusive for Early-Stage Disease Detection
June 1st 2025Multicancer early detection tests are revolutionizing cancer screening by using liquid biopsies to screen for multiple cancers from a single blood sample, enhancing patient outcomes by identifying cancers earlier.
Read More